The registration-directed trial evaluated the proprietary extended-release formulation across three cohorts: patients receiving 8.5mg doses once daily, twice daily, or a placebo. Investigators observed high statistical significance in hair regrowth, with the drug demonstrating a rapid onset of activity and consistent efficacy. No cardiac-related safety concerns or serious treatment-related adverse events were reported, supporting the drug’s profile as a viable alternative to existing treatments.

Building on earlier Phase 2/3 findings, the company now possesses six-month placebo-controlled data from more than 1,000 participants. This body of evidence positions VDPHL01 to potentially become the first FDA-approved oral pill for pattern hair loss in nearly three decades. By successfully navigating the registration-directed phase, Veradermics moves closer to addressing a market that has seen little pharmacological innovation for thirty years.